The researchers found that dry powder triple inhaler therapy of fluticasone-umeclidinium-vilanterol resulted in fewer COPD exacerbations compared to metered dose triple inhaler therapy of ...
The other single-inhaler on the market for COPD triple therapy, fluticasone-umeclidinium-vilanterol, is a dry-powder inhaler that does not contain hydrofluoroalkane-134a. In a 2024 JAMA report ...
Interventions: Patients entered a 4-week, open run-in period, receiving fluticasone propionate 50µg twice daily via a Diskus™ inhalation device. Patients whose asthma was well controlled ...
Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate ... 500µg twice daily from a Diskus™ inhaler for a 4-week run-in period, dependent ...
Hence, he should've abstained himself from the act. "Travis head's obnoxious behaviour during the course of the Melbourne test doesn't auger well for the gentleman's game..... sets the worst ...
William B. Feldman, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues compared the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice-daily metered dose ...
Objective To compare the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once daily dry powder inhaler, ...
We also excluded patients who received both budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol or who received triple therapy plus another maintenance inhaler on the cohort ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback